Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial
Supplementary Data
Supplementary Data
Supplementary Data
- Pdf file
Supplementary Figure 1
- docx file
Supplementary Table 1
- docx file
Supplementary Table 2
- docx file
Supplementary Table 3
- docx file